# New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS

- Link: https://www.thailand-business-news.com/pr-news/new-chemotherapy-free-immunotherapy-combination-for-follicular-lymphoma-listed-on-the-pbs
- Published: 2026-08-02T21:01:00+07:00
- Author: PR Newswire

|   |

 ◦ _Minjuvi__^(®)__ (tafasitamab), in combination with rituximab and lenalidomide,
   is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy
   combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults
   with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).^([)__^(
   1],[2])_
 ◦ _In the pivotal Phase 3 inMIND clinical trial, patients with R/R FL receiving
   the Minjuvi combination regimen experienced a significant improvement in progression-
   free survival, with a 57% reduction in the risk of disease progression, relapse
   or death, compared with placebo plus lenalidomide and rituximab.^([)__^(3])_
 ◦ _Follicular lymphoma is the second most common non-Hodgkin lymphoma (NHL), with
   over 10,000 Australians living with the disease and approximately 1,500 Australians
   diagnosed each year.^([)__^(4],[5])_

SINGAPORE, Aug. 2, 2026 /PRNewswire/ — Independent biopharmaceutical company Specialised
Therapeutics (ST) is pleased to announce the listing of Minjuvi^(®) (tafasitamab),
in combination with rituximab and lenalidomide, on the Pharmaceutical Benefits Scheme(
PBS) for the treatment of Australian adults with relapsed or refractory follicular
lymphoma (R/R FL) (Grade 1-3a).^([1]) This milestone follows the Australian registration
of Minjuvi for R/R FL by the Therapeutic Goods Administration (TGA) in April 2026,
via the Project Orbis process.^([6])

The PBS listing of Minjuvi marks the availability of the first and only chemotherapy-
free CD19 and CD20 dual-targeted immunotherapy combination regimen funded in Australia
for this group of patients.^([1],[2]) Effective 1 August 2026, eligible patients
with FL who have experienced relapses or disease progression on existing therapies
will now have equitable access to a new treatment option for this difficult-to-treat
condition.^([1])

"As the first new therapy to be reimbursed on the PBS for R/R FL in nine years, 
we are extremely proud to have partnered with Incyte to bring Minjuvi to Australia,"
said Carlo Montagner, ST Chief Executive Officer. "After securing TGA registration
for Minjuvi in R/R FL earlier this year, we have been focused on expediting PBS 
listing to ensure eligible Australian patients could have subsidised access to a
new treatment option that may help lower the risk of disease progression, relapse
or death, without delay."

ST entered into an exclusive distribution agreement with Incyte (NASDAQ:INCY) in
2021 to commercialise Minjuvi in Australia, New Zealand and Singapore.

Minjuvi is a CD19 targeting immunotherapy that works within a patient’s immune system
to help find and eliminate malignant B-cells.^([7]) In combination with rituximab
and lenalidomide, Minjuvi delivers a complementary immune-mediated approach that
helps control disease progression and supports improved long-term outcomes for patients
with follicular lymphoma.^([7])

The PBS reimbursement underscores the growing recognition of innovative immunotherapy-
based treatment strategies in follicular lymphoma and reinforces ST’s commitment
to improving access to life-changing therapies for patients across the Asia-Pacific
region.

"While follicular lymphoma can be a slow-growing disease that usually responds well
to the first treatment, most patients are not cured. Many patients experience frequent
relapses and require multiple therapies over their lifetime, which become progressively
less effective, especially for those whose disease comes back soon after initial
chemotherapy treatment," said Associate Professor Philip Thompson, Clinical Haematologist
at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital in Melbourne. "
Today’s PBS listing announcement is welcome news for the Australian clinical and
patient community, providing us with a new, chemotherapy-free immunotherapy treatment
for R/R FL."

Minjuvi is administered via intravenous (IV) infusion in a clinic or hospital setting.
^([7]) Patients with R/R FL receive up to 12 treatment cycles of Minjuvi, along 
with oral lenalidomide capsules, while rituximab is delivered intravenously for 
the first five cycles.^([7])

"Knowing that a chemotherapy-free immunotherapy is now funded by the PBS is an important
development for the follicular lymphoma community," said Sharon Winton, Chief Executive
Officer of Lymphoma Australia. "As patients manage the challenges of recurring disease,
this new treatment milestone offers a valuable option that is deeply meaningful 
to them and their families."

The PBS listing of Minjuvi for R/R FL means these patients will now have equitable
access to a new targeted immunotherapy combination treatment when they need it. 
It is important that patients with R/R FL speak with their doctor to understand 
the most suitable treatment option available for them.

For further details on Minjuvi, contact your healthcare professional and please 
refer to the approved Australian [Consumer Medicine Information](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2023-CMI-01799-1&d=20260421172310101)
or [Product Information](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2023-PI-01798-1)
available from the TGA website.

**PBS Information:**

This medicine is listed on the Pharmaceutical Benefits Scheme (PBS) — AUTHORITY 
REQUIRED. Refer to the PBS Schedule [www.pbs.gov.au](http://www.pbs.gov.au/) for
full authority information.

**Important Safety Information on Minjuvi****^([7])**

Minjuvi should be administered to patients with an active infection only if the 
infection is treated appropriately and well controlled. Patients with a history 
of recurring or chronic infections may be at increased risk of infection and should
be monitored appropriately. Patients should be advised to contact their healthcare
professionals if fever or other evidence of potential infection, such as chills,
cough or pain on urination, develops.

Treatment with Minjuvi in combination with lenalidomide and/or rituximab should 
not be initiated in female patients unless pregnancy has been excluded. In the inMIND
study, the most common adverse reactions were infections (68%), including viral 
infections (41%) and bacterial infections (27%); neutropenia (57%), rash (36.4%),
asthenia (34.9%), pyrexia (19%), thrombocytopenia (17%), anaemia (17%), infusion
related reaction (15.9%), pruritus (15.6%), and headache (10.4%). The most common
serious adverse reactions were infections (26%), including viral infections (13%)
and bacterial infections (6%), febrile neutropenia (2.8%), and pyrexia (1.8%).

Treatment with tafasitamab can cause serious or severe myelosuppression including
neutropenia, thrombocytopenia, and anaemia. Complete blood counts should be monitored
throughout treatment and prior to administration of each treatment cycle.

**Ends.**

**About Minjuvi****^(®)**** (tafasitamab)**

Minjuvi^(®) (tafasitamab) is a humanised Fc-modified cytolytic CD19-targeting monoclonal
antibody. Minjuvi incorporates an XmAb^(®) engineered Fc domain, which mediates 
B-cell lysis through apoptosis and immune effector mechanism including Antibody-
Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis(
ADCP).^([7]) Incyte licenses exclusive worldwide rights to develop and commercialise
Minjuvi from Xencor, Inc. 

In the U.S., Monjuvi^(®) (tafasitamab-cxix) is approved by the U.S. Food and Drug
Administration in combination with lenalidomide and rituximab for the treatment 
of adult patients with relapsed or refractory follicular lymphoma (FL). Additionally,
Monjuvi received accelerated approval in the United States in combination with lenalidomide
for the treatment of adult patients with relapsed or refractory DLBCL not otherwise
specified, including DLBCL arising from low grade lymphoma, and who are not eligible
for ASCT. 

Monjuvi is not indicated and is not recommended for the treatment of patients with
relapsed or refractory marginal zone lymphoma outside of controlled clinical trials.

In Europe, Minjuvi^(®) (tafasitamab) received conditional Marketing Authorisation
from the European Medicines Agency in combination with lenalidomide, followed by
Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory
DLBCL who are not eligible for ASCT. In addition, in December 2025, the EMA approved
Minjuvi, in combination with lenalidomide and rituximab, for the treatment of adult
patients with relapsed or refractory FL (Grade 1-3a) after at least one line of 
systemic therapy. 

In Japan, Minjuvi is approved in combination with lenalidomide for the treatment
of adults with relapsed or refractory DLBCL. Minjuvi is also approved in combination
with rituximab and lenalidomide for adult patients with relapsed or refractory FL(
2L+ FL). 

In Australia, Minjuvi^(®) (tafasitamab) is indicated in combination with lenalidomide
followed by Minjuvi monotherapy for the treatment of adult patients with relapsed
or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous
stem cell transplant (ASCT).^([7])

**▼ **This medicine is included in the TGA Black Triangle Scheme. Please report 
suspected adverse events to the TGA.^([7])

XmAb^(®) is a registered trademark of Xencor, Inc. 

Monjuvi and Minjuvi are registered trademarks of Incyte. 

**About the inMIND Study^([)****^(3])**

A global, double-blind, randomised, placebo-controlled Phase 3 study, _inMIND_ (
NCT04680052) evaluated the efficacy and safety of Minjuvi (tafasitamab) in combination
with rituximab and lenalidomide compared with placebo in combination with rituximab
and lenalidomide in patients with relapsed or refractory follicular lymphoma (FL)
Grade 1 to 3a or relapsed or refractory nodal, splenic or extranodal marginal zone
lymphoma (MZL). The study enrolled a total of 654 adults (age ≥18 years), including
548 participants with R/R FL. 54 Australians participated in the study across 12
local trial sites around the country.

The primary endpoint of the study is progression-free survival (PFS) by investigator
assessment in the FL population, and the key secondary endpoints are PFS in the 
overall population as well as positron emission tomography complete response (PET-
CR) and overall survival (OS) in the FL population.

The clinical trial met its primary endpoint, with the data demonstrating a statistically
significant and clinically meaningful improvement in progression-free survival (
PFS) in comparison to placebo added to lenalidomide and rituximab. Patients receiving
Minjuvi in combination with rituximab and lenalidomide achieved a median PFS by 
investigator assessment of 22.4 months (95% CI, 19.2-not evaluable [NE]) compared
to 13.9 months (95% CI, 11.5-16.4) in the control arm (hazard ratio [HR]: 0.43 [
95% CI, 0.32-0.58]; P<0.0001). The PFS assessed by an Independent Review Committee(
IRC) was consistent with investigator-based results. Median PFS by IRC was not reached(
95% CI, 19.3-NE) in the Minjuvi group versus 16.0 months (95% CI, 13.9-21.1) in 
the placebo group (HR: 0.41 [95% CI, 0.29-0.56].

Minjuvi was generally well-tolerated, with a manageable safety profile. Safety and
tolerability were comparable with the addition of Minjuvi to lenalidomide in combination
with rituximab. The most common adverse reactions in the Phase 3 study (≥20%) in
patients receiving Minjuvi, excluding laboratory abnormalities, were respiratory
tract infections (including COVID-19 infection and pneumonia), diarrhoea, rash, 
fatigue, constipation, musculoskeletal pain and cough.

**About Specialised Therapeutics **

Founded in 2007, Specialised Therapeutics is an independent specialty pharmaceutical
company, providing novel therapies and technologies to patients in Australia, New
Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with 
global pharmaceutical, biotech and diagnostic companies to bring novel healthcare
opportunities to patients who are impacted by a range of diseases. ST has built 
a strong track record of success, navigating complex regulatory, reimbursement and
commercialisation environments in its diverse regions across multiple therapeutic
areas. The ST mission is to provide specialty therapies where there is an unmet 
need to communities that would otherwise not have ready access to such therapies.
The company’s broad therapeutic portfolio currently includes novel agents in oncology,
haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although
it is not confined to these areas.           

Additional information can be found at [www.stbiopharma.com](http://www.stbiopharma.com/).

**REFERENCES:**

  |

[1]. Australian Government, Department of Health, Disability and Ageing. PBS Schedule: [PBS Publications & Downloads](https://www.pbs.gov.au/browse/publications) [August 2026].

  |  
 |

[2]. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 3.2026.

  |  
 |

[3]. Sehn LH, et al. Lancet. 2026 Jan 10;407(10524):133-146.

  |  
 |

[4]. Lymphoma Australia. Types of Lymphoma: [Follicular Lymphoma](https://www.leukaemia.org.au/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/follicular-lymphoma/). [Accessed July 2026].

  |  
 |

[5]. Australian Institute of Health and Welfare (AIHW). Cancer Data in Australia: Prevalence Data Workbook – [Blood Cancer Histology](https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/blood-cancer-incidence-and-survival-by-histology). [Accessed July 2026].

  |  
 |

[6]. Therapeutic Goods Administration. Australian Register of Therapeutic Goods (ARTG): [MINJUVI (tafasitamab)](https://www.tga.gov.au/resources/artg/387298). [Accessed July 2026].

  |  
 |

[7]. MINJUVI Australian Product Information. 20 April 2026.

  |

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS ](http://www.prnasia.com/story/archive/5016596_CN16596_0?rand=184833)
